Diabetic ketoacidosis: a challenging diabetes phenotype

Cliona Small, Aoife M Egan, El Muntasir Elhadi, Michael W O’Reilly, Aine Cunningham and Francis M Finucane
HRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, Galway, Ireland

Summary
We describe three patients presenting with diabetic ketoacidosis secondary to ketosis prone type 2, rather than type 1 diabetes. All patients were treated according to a standard DKA protocol, but were subsequently able to come off insulin therapy while maintaining good glycaemic control. Ketosis-prone type 2 diabetes (KPD) presenting with DKA has not been described previously in Irish patients. The absence of islet autoimmunity and evidence of endogenous beta cell function after resolution of DKA are well-established markers of KPD, but are not readily available in the acute setting. Although not emphasised in any current guidelines, we have found that a strong family history of type 2 diabetes and the presence of cutaneous markers of insulin resistance are strongly suggestive of KPD. These could be emphasised in future clinical practice guidelines.

Background
The occurrence of hyperglycaemic ketosis and diabetic ketoacidosis (DKA) as manifestations of type 2 rather than type 1 diabetes has been well established for some time (1, 2). However, awareness of this among clinicians is variable, with a widely held misconception that ketosis is synonymous with absolute rather than relative insulin deficiency and with type 1 diabetes. Many guidelines on the management of DKA do not highlight the possibility of ‘ketosis-prone diabetes’ (KPD) (3, 4), though some do (5, 6). Heterogeneity exists in the approach to diagnosing KPD. Some authorities emphasise adiposity and ethnicity (7), whereas others consider beta-cell function and markers of beta-cell autoimmunity in assessing the likelihood of KPD (8). However, applying these criteria in clinical practice can be challenging and other factors such as family history and the presence of cutaneous manifestations of insulin resistance such as skin tags or acanthosis nigricans might help to refine the diabetes

Learning points:
• Even in white patients, DKA is not synonymous with type 1 diabetes and autoimmune beta cell failure. KPD needs to be considered in all patients presenting with DKA, even though it will not influence their initial treatment.
• Aside from markers of endogenous beta cell function and islet autoimmunity, which in any case are unlikely to be immediately available to clinicians, consideration of family history of type 2 diabetes and cutaneous markers of insulin resistance might help to identify those with KPD and are more readily apparent in the acute setting, though not emphasised in guidelines.
• Consideration of KPD should never alter the management of the acute severe metabolic derangement of DKA, and phasing out of insulin therapy requires frequent attendance and meticulous and cautious surveillance by a team of experienced diabetes care providers.
phenotype and differentiate between type 1 and ketosis prone type 2 diabetes variants. This would have important implications for optimising therapy for individual patients who may avoid unnecessary indefinite insulin therapy. We sought to identify areas of uncertainty and potentially informative clinical features in the assessment and treatment of patients presenting with diabetic ketoacidosis.

**Case presentation**

**Case 1**

A 44-year-old Sudanese male presented to our emergency department with an episode of collapse, associated with a two-week history of severe thirst, polyuria, nocturia, lethargy and 10 kg weight loss. He had no history of note, was on no medications, had no allergies and never drank alcohol. He was drowsy with slurred speech but no focal neurological deficits. He was severely dehydrated with dry mucus membranes, reduced skin turgidity, tachycardia and hypotension. As shown in Table 1, he had severe hyperglycaemia, ketonaemia and metabolic acidosis with low pH and bicarbonate and high lactate levels as well as severe hypernatraemia and hyperosmolar state. He had acute kidney injury secondary to rhabdomyolysis (creatine kinase 45 000 µ/L, normal <308). He was intubated and ventilated and transferred to the intensive care unit. He was managed according to our DKA/HHS protocol with aggressive intravenous fluid resuscitation and cautious normalisation of his sodium levels. He required six units per hour of intravenous insulin to restore euglycaemia over the initial 12 h. On day two, he required continuous veno-venous haemodiafiltration for three days with subsequent normalisation of renal function. Initially on this, his corrected sodium dropped from 157 to 143 over four hours, so a hypertonic saline infusion was used for 48 h to avoid osmotic demyelination syndrome from over-rapid correction of hypernatraemia. He improved and was changed to a multiple daily injection (MDI) regime of eight units of insulin aspart with meals and 20 units of insulin detemir at night. There was no family history of diabetes, nor were there any skin tags or acanthosis nigricans, though the patient had a centripetal fat distribution on examination. He reported a high intake of sugar-sweetened beverages in the weeks prior to admission. Notwithstanding his presentation with diabetic ketoacidosis, his weight loss and the absence of a family history of diabetes or cutaneous markers of insulin resistance, his elevated BMI and central fat distribution, his ethnicity and the severity of his hyperosmolar state suggested a possible underlying type 2 diabetes phenotype. We discharged him on MDI insulin and started metformin therapy six weeks after diagnosis, which led to a reduction in his insulin requirements to zero eight weeks after diagnosis and improvement in his HbA1c to 52 mmol/mol. One month after diagnosis, his C-peptide levels suggested endogenous insulin secretion and intact beta-cell function. Thereafter, his anti-glutamic acid decarboxylase (GAD) and anti-Islet cell (IC2) antibodies were negative. Fourteen months after initial presentation,

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Anthropometric and metabolic characteristics of three patients at initial presentation with diabetic ketoacidosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>Patient 2</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>31</td>
</tr>
<tr>
<td><strong>Plasma glucose (mmol/L)</strong></td>
<td>67.1</td>
</tr>
<tr>
<td><strong>HBA1c (mmol/mol)</strong></td>
<td>96</td>
</tr>
<tr>
<td><strong>Plasma ketones (mmol/L)</strong></td>
<td>7.8</td>
</tr>
<tr>
<td><strong>Urine ketones (semi-quantitative)</strong></td>
<td>‘4+’</td>
</tr>
<tr>
<td><strong>pH (arterial)</strong></td>
<td>7.28</td>
</tr>
<tr>
<td><strong>pCO₂ (arterial)</strong></td>
<td>4.2</td>
</tr>
<tr>
<td><strong>HC0₃⁻ (mmol/L)</strong></td>
<td>14.7</td>
</tr>
<tr>
<td><strong>Plasma lactate (mmol/L)</strong></td>
<td>6.8</td>
</tr>
<tr>
<td><strong>Plasma sodium (mmol/L)</strong></td>
<td>167</td>
</tr>
<tr>
<td><strong>Triglycerides (mmol/L)</strong></td>
<td>2.9</td>
</tr>
<tr>
<td><strong>eGFR (ml/min)</strong></td>
<td>10</td>
</tr>
<tr>
<td><strong>Serum osmolality (mmol/kg)</strong></td>
<td>399</td>
</tr>
<tr>
<td><strong>Anti-GAD antibodies (U/ml)</strong></td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-islet cell (IC2) antibodies (U/ml)</strong></td>
<td>Negative</td>
</tr>
<tr>
<td><strong>C-peptide (pmol/L)</strong></td>
<td>787*</td>
</tr>
</tbody>
</table>

*One month after the initial presentation. **One week after initial presentation.

BMI, body mass index; eGFR, estimated glomerular filtration rate; GAD, glutamic acid decarboxylase.
he continues to do well on metformin monotherapy with an HbA1c in the non-diabetic range at 42 mmol/mol.

Case 2

A previously well 45-year-old white Irish male farmer presented to the emergency department with a one-day history of abdominal pain and vomiting with associated dyspnoea, preceded by a four-week history of polyuria, polydipsia, lethargy and 9 kg weight loss. On examination, he appeared severely dehydrated, with hypotension, tachycardia and tachypnoea. He had a large para-umbilical hernia, which appeared strangulated and obstructed on an abdominal CT scan. Moreover, he had diabetic ketoacidosis as outlined in Table 1. His renal and liver function and lactate were normal. We considered the severity of his DKA was aggravated by his bowel obstruction, notwithstanding his normal lactate level. The standard protocol for managing DKA was initiated with fluid resuscitation, electrolyte repletion and intravenous insulin prior to laparoscopic mesh repair of his hernia. He required in excess of 100 units of insulin per day initially to restore euglycaemia. He had an elevated BMI, a centripetal fat distribution, axillary and cervical skin tags and acanthosis nigricans and a strong family history of T2DM, all consistent with an insulin-resistant phenotype. He also had a suboptimal lipid profile and microalbuminuria at diagnosis. We established the patient on a twice-daily mixed insulin regime prior to discharge and noted a progressive reduction in insulin requirements with restoration of glycaemic control. We started metformin five weeks after his initial presentation and stopped insulin completely three weeks later, when his HbA1c had improved to 48 mmol/mol. Anti-GAD and anti-IC2 antibodies were negative. Forty-one months after his initial presentation, it was normal at 37 mmol/mol on metformin 850 mg bd. The acanthosis nigricans and high BMI at presentation as well as the strong family history suggested type 2 rather than type 1 diabetes, notwithstanding this man’s age, ethnicity and presentation with DKA. The negative antibodies and normalisation of glucose control without an ongoing requirement for insulin were felt to confirm the diagnosis.

Discussion

These cases highlight the fact that DKA is not synonymous with type 1 diabetes and permanent, autoimmune destruction of beta cells, but may arise from reversible beta cell failure in patients with phenotypic features of type 2 diabetes. In our first patient, even though there was no family history of type 2 diabetes or cutaneous manifestations of insulin resistance, his ethnicity, centripetal fat distribution and degree of hyperosmolarity at presentation suggested an insulin-resistant phenotype. Our approach (as with any patient with DKA) was to initiate treatment with insulin acutely and to consider introducing an insulin sensitisier (metformin) and reducing the insulin dose only after glycaemic control was restored and the severe metabolic derangements had fully resolved. We did not rely on islet autoantibodies or C-peptide levels in making a provisional diagnosis of KPD. Rather, we were guided by clinical features apparent at the outset. We were cautious to supervise his insulin dose reduction and blood glucose monitoring closely, with twice-weekly telephone contact with the diabetes nurse and regular clinical assessment.

Our second patient was similar to the first in that he had osmotic symptoms in the weeks prior to presentation and a centripetal fat distribution. However, KPD has not
previously been described in a patient of white Irish ethnicity, usually occurring in patients of black African or Asian descent (9). Notwithstanding his ethnicity, the prominence of his insulin-resistant phenotype with skin tags, acanthosis, a strong family history of type 2 diabetes and high insulin requirements as well as his dyslipidaemia and prevalent microalbuminuria at diagnosis mandated consideration of KPD. As in all three cases, treatment according to our DKA protocol was initiated acutely and the consideration of KPD only influenced management once the acute metabolic derangements had been reversed with fluid resuscitation and insulin.

Our third case was also atypical of a patient with newly diagnosed type 2 diabetes, given his relative youth. However, the presence of cutaneous markers of insulin resistance and a very strong family history of type 2 diabetes prompted us to consider KPD, after his acute metabolic derangements were managed with fluids and insulin. All three patients were negative for anti-GAD and anti-IC2 antibodies, but (as in the cases here) often these results are only available weeks after the initial presentation, at least in our institution, so do not currently inform our initial phenotypic assessment. Nonetheless, a heavy emphasis is placed on their utility in a number of proposed classification schemes for KPD, in an attempt to predict better which patients might ultimately be weaned off insulin therapy vs requiring it for life (8). Some also suggest BMI is an important consideration (7), but we regard it as a relatively crude and unhelpful marker of excess body fat or its distribution. The ‘αβ’ system (8), which considers beta-cell function (measured with C-peptide) as well as islet autoimmunity, seems the best to us although we had not routinely measured C-peptide in all potential KPD patients up to now and in our first two patients here, it was measured weeks after their initial presentation. Moreover, although international clinical guidelines have recently started to emphasise KPD as an important consideration in patients presenting with DKA, consensus on the optimal way to diagnose and manage KPD is lacking.

Our patients highlight the variability in terms of age, ethnicity and adiposity associated with ketosis-prone type 2 diabetes. The mechanistic basis for absolute, albeit transient absolute beta-cell failure in KPD is not fully established but is thought to involve glucotoxicity secondary to subacute or chronic hyperglycaemia, probably aggravated by underlying insulin resistance (10). Although rarer causes of ‘non-type 1’ DKA such as HNF1A MODY (11) and euglycaemic DKA in patients on SGLT2 inhibitors (12) have been described, KPD is the most likely alternative diagnosis to type 1 diabetes. In carefully reducing the insulin dose over weeks where KPD is suspected, we are adopting an approach of hoping for the best, anticipating the worst and taking what comes.

Declaration of interest
Francis Finucane has received honoraria, travel grants and has served on advisory boards for Novo Nordisk, Eli Lilly, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Merck-Serono, Boehringer Ingelheim, Janssen and Novartis. Aoife Egan has received honoraria and travel grants from Novo Nordisk, Eli Lilly, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Boehringer Ingelheim, Janssen and Novartis. Aine Cunningham, El Muntasir Elhadi, Michael W O’Reilly and Cliona Small have no conflicts of interest to declare.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent
All patients provided written, signed, informed consent for their anonymised information to be included in this case series.

Author contribution statement
Each author contributed to the study design, description of the cases and data collection and analysis. Francis M Finucane was the treating physician for two patients and Michael W O’Reilly for the third.

References

http://www.edmcasereports.com


Received in final form 15 December 2016
Accepted 31 January 2017